This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neoplasms  • Dermatology, Other  • Alert me on articles by topic

Unlikely Survival Benefit in Melanoma

Urbà González, MD, PhD

Arch Dermatol. 2007;143(6):775-776.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Sentinel-node biopsy or nodal observation in melanoma
Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group
N Engl J Med. 2006;355:1307-1317

Question: Does lymphadenectomy performed for microscopic (sentinel node biopsy [SNB]) rather than macroscopic (clinically detectable) nodal disease prolong survival in patients with melanoma?

Design: Randomized controlled trial.

Setting: Multicenter trial performed in hospitals and health centers in the United States, Australia, and Europe.

Participants: A total of 1347 patients with primary melanomas of 1.2 to 3.5 mm in thickness were randomized, 20 patients were lost after randomization, and the remaining 1327 were from North America (n = 221), Europe (n = 386), and Australia (n = 720), with 1269 patients finishing the study. Study groups had similar baseline characteristics, and patients were randomly assigned to SNB or observation in a 60:40 ratio.

Interventions: Patients with a primary cutaneous melanoma were randomly assigned to the following 2 groups: (1) . . . [Full Text of this Article]

Comment


AUTHOR INFORMATION
Department of Dermatology, Research Unit for Evidence-Based Dermatology, Clinica Plató, Barcelona, Spain

RELATED ARTICLES

Systemic Adjuvant Therapy for Patients With High-Risk Melanoma
Kenneth Y. Tsai
Arch Dermatol. 2007;143(6):779-782.
EXTRACT | FULL TEXT  

The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive
Matthew H. Kanzler
Arch Dermatol. 2007;143(6):785-787.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sentinel Node Biopsy: Facts to Clear the Alleged Clouds
Morton and Elashoff
Arch Dermatol 2008;144:685-686.
FULL TEXT  

Sentinel Node Biopsy: Facts to Clear the Alleged Clouds--Reply
Gonzalez
Arch Dermatol 2008;144:687-687.
FULL TEXT  

Lymphatic Mapping and Sentinel Node Biopsy: The Data Unclouded by Speculation--Reply
Kanzler
Arch Dermatol 2008;144:688-689.
FULL TEXT  

The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive
Kanzler
Arch Dermatol 2007;143:785-787.
FULL TEXT